FDA Approves Itovebi for Locally Advanced, Metastatic Breast Cancer

WEDNESDAY, Oct. 16, 2024-- The U.S. Food and Drug Administration approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor...